PanTracer Portfolio

PanTracer Portfolio

Liquid and tissue CGP testing solutions for advanced-stage solid tumors 

Two Samples, One Story: The Future of CGP in Oncology

Powerful simple solutions for therapy-selection

  • Guideline-driven tests
  • Easy to interpret and actionable reports
  • Rapid turn-around - Liquid 7 days or less and tissue 8-10 days
NeoPanTracer portfolio
Button style
Text link
Body

Liquid and tissue comprehensive genomic profiling (CGP) testing solutions for patients with advanced-stage solid tumors

PanTracer™ LBx and PanTracer™ Tissue

Next-generation diagnostic solutions for patients with advanced-stage solid tumors.

​

The PanTracer portfolio empowers oncologists with actionable genomic insights for confident, real-time treatment decisions. Whether you’re selecting approved targeted therapies or exploring clinical trials, working from a liquid or tissue biopsy, PanTracer ensures that you’re equipped with the insights you need.

PanTracer Tissue and PanTracer LBx work together seamlessly to maximize genomic insights. Order these tests independently or as complementary tests based on your patient’s unique needs. When every answer counts, PanTracer is there to support you.

dna icon

>500 Genes
PanTracer Tissue and PanTracer LBx detect alterations in over 500 genes including SNVs, InDels, CNVs, fusions, MSI, and TMB

dna icon

Rapid Turnaround Time​
Results in 8-10 days for PanTracer Tissue, and within 7 days for PanTracer LBx

dna icon

Actionable and informative reports​​
Clear, concise reports to support rapid clinical decisions

dna icon

Minimal specimen requirements​​​
Results from a simple blood draw for PanTracer LBx or as few as 10 FFPE slides for PanTracer Tissue

PanTracer Tissue

Tab content
PanTracer Tissue

PanTracer LBx

Tab content
PanTracer LBx

PanTracer Tissue + HRD

Tab content
PanTracer Tissue + HRD